FLT4 antibody (Extracellular Domain) (Biotin)

Catalog No. ABIN115160

The Mouse Monoclonal anti-FLT4 antibody has been validated for WB and EIA. It is suitable to detect FLT4 in samples from Human. There is 1 publication available.

Quick Overview for FLT4 antibody (Extracellular Domain) (Biotin) (ABIN115160)

Target: FLT4 (Fms-Related Tyrosine Kinase 4 (FLT4))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This FLT4 antibody is conjugated to Biotin

Application: Western Blotting (WB), Enzyme Immunoassay (EIA)

Clone: 3C3

Product Details anti-FLT4 Antibody (Biotin)

Binding Specificity: Extracellular Domain

Specificity: Detects Human VEGFR-3/FLT-4.

Purification: Affinity Chromatography on Protein G .

Immunogen: Purified recombinant human Vascular Endothelial Growth Factor Receptor 3 (rh VEGFR-3/FLT-4) extracellular domain.

Isotype: IgG1

Application Details

Application Notes: ELISA: 0.5-1.5 μg/mL in direct ELISA, allows detection of 0.25-0.5 ng/well. Western blot: 0.5-1 μg/mL, detection limit is approximately 5 ng/lane under reducingconditions.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Handling

Reconstitution: Restore in sterile water to a concentration of > 0.5 mg/mL.

Buffer: 0.1 M Tris-Cl, 0.1 M NaCl, pH 7.4 containing BSA (50x) as stabilizer and 0.02 % Sodium Azide as preservative.

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Avoid repeated freezing and thawing.

Storage: 4 °C/-20 °C

Storage Comment: The lyophilized IgG is stable at 2-8 °C for one month and for one year from despatch when kept at -20 °C. When reconstituted in sterile water to a concentration of > 0.5 mg/ml the antibody is stable for six weeks at 2-8 °C or at -20 °C for longer. Aliquot to

Expiry Date: 12 months

References for anti-FLT4 antibody (Biotin) (ABIN115160)

Davids, Davids, Charlton, Ng, Chong, Laubscher, Dar, Hodge, Soong, Goh: "Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma." in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 27, Issue 26, pp. e97-100, (2009) (PubMed).

Target Details for FLT4

Target: FLT4 (Fms-Related Tyrosine Kinase 4 (FLT4))

Alternative Name: VEGFR-3 / Flt-4

Background: VEGFR-3/FLT-4, belongs to the class III subfamily of receptor tyrosine kinases. VEGFR-3/FLT-4 mediates the angiogenic activity of VEGF-C and VEGF-D on lymphatic endothelial cells.Synonyms: FLT4, Tyrosine-protein kinase receptor FLT4, VEGF Receptor 3, VEGFR3, Vascular endothelial growth factor receptor 3

Gene ID: 2324

NCBI Accession: NP_002011

UniProt: P35916

Pathways: RTK Signaling, Signaling Events mediated by VEGFR1 and VEGFR2, VEGF Signaling